Laboratory Corporation of America Holdings (LH)
After hours:
| Previous close | 214.65 |
| Open | 213.76 |
| Bid | 218.02 x 800 |
| Ask | 218.99 x 800 |
| Day's range | 212.22 - 218.60 |
| 52-week range | 200.32 - 280.72 |
| Volume | |
| Avg. volume | 623,054 |
| Market cap | 19.329B |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | 15.53 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.88 (1.32%) |
| Ex-dividend date | 22 Feb 2023 |
| 1y target est | N/A |
- Business Wire
Ovia HealthTM Expands Digital Platform Capabilities to Include Menopause Tracking
BOSTON, February 22, 2023--Ovia Health, a trusted digital health platform for women and families, today announced the expansion of its Ovia® app, which will now allow women to track menopause symptoms and access valuable resources and support to address the transition to menopause/perimenopause. The technology is available through Ovia’s consumer application and enterprise offerings for employers and health plans.
- Business Wire
Labcorp Announces 2022 Fourth Quarter and Full-Year Results
BURLINGTON, N.C., February 16, 2023--Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the fourth quarter and year ended Dec. 31, 2022, full-year 2023 guidance.
- Business Wire
Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea
BURLINGTON, N.C., February 09, 2023--Labcorp (NYSE: LH), a leading global life sciences company, today announced that the new company to be formed by the planned spin-off of its Clinical Development business will be known as Fortrea. Upon completion of the spin-off from Labcorp, Fortrea will operate as an independent, publicly traded global CRO that offers comprehensive drug and medical device development services. With over 19,000 people, Fortrea will provide Phase I through IV clinical trial m
